Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAH9901 is a transdermal patch formulation of methylphenidate developed by Taihe Pharmaceutical for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). As a central nervous system stimulant, it acts by inhibiting the reuptake of dopamine and norepinephrine through the blockade of the dopamine transporter (DAT) and norepinephrine transporter (NET), respectively. This inhibition leads to increased concentrations of these catecholamines in the synaptic cleft, enhancing neurotransmission in brain regions associated with attention and impulse control. The transdermal delivery system is designed to provide a controlled, sustained release of the medication, potentially offering improved patient compliance and a smoother pharmacokinetic profile compared to traditional oral formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylphenidate (Taihe Pharmaceutical).